Aortic elastic properties Effects of carvedilol versus nebivolol

The aim of this study was to compare the effects of the new generation beta-blocker anti-hypertensive drugs carvedilol and nebivolol on aortic elastic properties which are important indicators of hypertension-related morbidity and mortality. A total of 50 patients who had been diagnosed with stage 1 hypertension according to the Joint National Committee (JNC) VII criteria and who had not received any anti-hypertensive treatment were enrolled in this study. Patients were randomized to receive either 25 mg/day carvedilol (n = 25) or 5 mg/day nebivolol (n = 25) for 3 months at the beginning of the study. Three patients (1 in the carvedilol group, 2 in the nebivolol group) who did not attend 3 month follow-up measurements were excluded from the study. The study was completed with 47 patients (25 women; mean age: 49 +/- 9 years). The aortic elastic parameters such as aortic strain (AS), aortic distensibility (AD), and aortic stiffness index (ASI) were measured by echocardiography. Carvedilol and nebivolol provided a similar decline in both systolic and diastolic blood pressures (-12/-7 mmHg, p < 0.0001 and -12/-7 mmHg, p = 0.002, respectively). Both carvedilol and nebivolol induced a significant decrease in heart rate (-aEuro parts per thousand 15 bpm, p < 0.0001, -aEuro parts per thousand 17 bpm, p < 0.0001, respectively). Even though the heart rate at the end of the treatment was lower for the nebivolol group, the rate of decrease of heart rates between carvedilol and nebivolol groups was not statistically significant (p = 0.074). Both groups demonstrated improvements in the diastolic functions of the left ventricle where certain values showed more improvement for the nebivolol group. Both groups showed improvements in AS and AD rates compared to basal rates; however, these improvements were not statistically significant. Although the improvement rates in AS, AD, and ASI were higher in the nebivolol group compared to the carvedilol group, the differences were not statistically significant (p = 0.091, p = 0.095, p = 0.259, respectively). Both carvedilol and nebivolol induced a decrease in blood pressure and heart rate and showed an improvement in left ventricular diastolic functions. It was observed that both drugs did not cause deterioration in the aortic elastic properties but a slight improvement was seen. However, this improvement was not statistically significant. The improvement was more explicit in the nebivolol group. It may be concluded that nebivolol is slightly superior to carvedilol in reducing heart rate and improving left ventricular diastolic functions. However, further long-term studies with larger sample sizes should be performed in order to better define the effects of both drugs.

Dergi Adı HERZ
Dergi Cilt Bilgisi 38
Dergi Sayısı 3
Sayfalar 299 - 305
Yayın Yılı 2013
Eser Adı
[dc.title]
Aortic elastic properties Effects of carvedilol versus nebivolol
Yazar
[dc.contributor.author]
Sayin, M. R.
Yazar
[dc.contributor.author]
Aydin, M.
Yazar
[dc.contributor.author]
Dogan, S. M.
Yazar
[dc.contributor.author]
Karabag, T.
Yazar
[dc.contributor.author]
Cetiner, M. A.
Yazar
[dc.contributor.author]
Aktop, Z.
Yayın Yılı
[dc.date.issued]
2013
Yayıncı
[dc.publisher]
URBAN & VOGEL
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
The aim of this study was to compare the effects of the new generation beta-blocker anti-hypertensive drugs carvedilol and nebivolol on aortic elastic properties which are important indicators of hypertension-related morbidity and mortality. A total of 50 patients who had been diagnosed with stage 1 hypertension according to the Joint National Committee (JNC) VII criteria and who had not received any anti-hypertensive treatment were enrolled in this study. Patients were randomized to receive either 25 mg/day carvedilol (n = 25) or 5 mg/day nebivolol (n = 25) for 3 months at the beginning of the study. Three patients (1 in the carvedilol group, 2 in the nebivolol group) who did not attend 3 month follow-up measurements were excluded from the study. The study was completed with 47 patients (25 women; mean age: 49 +/- 9 years). The aortic elastic parameters such as aortic strain (AS), aortic distensibility (AD), and aortic stiffness index (ASI) were measured by echocardiography. Carvedilol and nebivolol provided a similar decline in both systolic and diastolic blood pressures (-12/-7 mmHg, p < 0.0001 and -12/-7 mmHg, p = 0.002, respectively). Both carvedilol and nebivolol induced a significant decrease in heart rate (-aEuro parts per thousand 15 bpm, p < 0.0001, -aEuro parts per thousand 17 bpm, p < 0.0001, respectively). Even though the heart rate at the end of the treatment was lower for the nebivolol group, the rate of decrease of heart rates between carvedilol and nebivolol groups was not statistically significant (p = 0.074). Both groups demonstrated improvements in the diastolic functions of the left ventricle where certain values showed more improvement for the nebivolol group. Both groups showed improvements in AS and AD rates compared to basal rates; however, these improvements were not statistically significant. Although the improvement rates in AS, AD, and ASI were higher in the nebivolol group compared to the carvedilol group, the differences were not statistically significant (p = 0.091, p = 0.095, p = 0.259, respectively). Both carvedilol and nebivolol induced a decrease in blood pressure and heart rate and showed an improvement in left ventricular diastolic functions. It was observed that both drugs did not cause deterioration in the aortic elastic properties but a slight improvement was seen. However, this improvement was not statistically significant. The improvement was more explicit in the nebivolol group. It may be concluded that nebivolol is slightly superior to carvedilol in reducing heart rate and improving left ventricular diastolic functions. However, further long-term studies with larger sample sizes should be performed in order to better define the effects of both drugs.
Açıklama
[dc.description]
WOS: 000318703600010
Açıklama
[dc.description]
PubMed: 23263241
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Essential hypertension
Konu Başlıkları
[dc.subject]
Carvedilol
Konu Başlıkları
[dc.subject]
Nebivolol
Konu Başlıkları
[dc.subject]
Aortic elastic properties
Konu Başlıkları
[dc.subject]
Adrenergic beta-antagonists
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0340-9937
İlk Sayfa Sayısı
[dc.identifier.startpage]
299
Son Sayfa Sayısı
[dc.identifier.endpage]
305
Dergi Adı
[dc.relation.journal]
HERZ
Dergi Sayısı
[dc.identifier.issue]
3
Dergi Cilt Bilgisi
[dc.identifier.volume]
38
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1007/s00059-012-3695-9
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/2100
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
17
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
08 Şubat 2024 12:49
Google Kontrol
Tıklayınız
nebivolol carvedilol aortic improvement significant statistically diastolic decrease functions elastic respectively) showed patients improvements groups mg/day properties compared thousand effects anti-hypertensive induced However treatment ventricular demonstrated define between better should performed (-aEuro though -aEuro further
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms